GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
39.01
+1.37 (3.64%)
At close: Apr 3, 2025, 4:00 PM
38.50
-0.51 (-1.31%)
After-hours: Apr 3, 2025, 8:00 PM EDT
GSK Employees
GSK plc had 68,629 employees as of December 31, 2024. The number of employees decreased by 1,583 or -2.25% compared to the previous year.
Employees
68,629
Change (1Y)
-1,583
Growth (1Y)
-2.25%
Revenue / Employee
$572,359
Profits / Employee
$46,973
Market Cap
78.18B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
Dec 31, 2023 | 70,212 | 812 | 1.17% |
Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
Dec 31, 2019 | 99,437 | 3,947 | 4.13% |
Dec 31, 2018 | 95,490 | -2,972 | -3.02% |
Dec 31, 2017 | 98,462 | -838 | -0.84% |
Dec 31, 2016 | 99,300 | -1,955 | -1.93% |
Dec 31, 2015 | 101,255 | 3,334 | 3.40% |
Dec 31, 2014 | 97,921 | -1,530 | -1.54% |
Dec 31, 2013 | 99,451 | -37 | -0.04% |
Dec 31, 2012 | 99,488 | 2,099 | 2.16% |
Dec 31, 2011 | 97,389 | 928 | 0.96% |
Dec 31, 2010 | 96,461 | -3,452 | -3.46% |
Dec 31, 2009 | 99,913 | 910 | 0.92% |
Dec 31, 2008 | 99,003 | -4,480 | -4.33% |
Dec 31, 2007 | 103,483 | 788 | 0.77% |
Dec 31, 2006 | 102,695 | 1,967 | 1.95% |
Dec 31, 2005 | 100,728 | 709 | 0.71% |
Dec 31, 2004 | 100,019 | -900 | -0.89% |
Dec 31, 2003 | 100,919 | -3,580 | -3.43% |
Dec 31, 2002 | 104,499 | -2,971 | -2.76% |
Dec 31, 2001 | 107,470 | -47 | -0.04% |
Dec 31, 2000 | 107,517 | -1,524 | -1.40% |
Dec 31, 1999 | 109,041 | -7,780 | -6.66% |
Dec 31, 1998 | 116,821 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GSK News
- 7 hours ago - GSK resolves patent lawsuit against Pfizer over RSV vaccines - Reuters
- 10 hours ago - New Study Shows Shingles Vaccine Linked To 20% Lower Dementia Risk, GSK Stock Pops - Benzinga
- 1 day ago - Pharma stocks survive market rout on tariff exemption, but uncertainty continues - Reuters
- 7 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in GSK plc Lawsuit - GSK - PRNewsWire
- 9 days ago - Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older - Business Wire
- 9 days ago - US FDA approves GSK's urinary tract infection drug - Reuters
- 9 days ago - GSK studying if best-selling shingles vaccine lowers dementia risk - Reuters
- 10 days ago - GSK says European regulator reviewing expanded use of asthma drug Nucala - Reuters